Shopping Cart
Remove All
Your shopping cart is currently empty
Soraprazan (BYK61359) is a selective potassium channel inhibitor that inhibits gastric acid secretion and ameliorates age-related eye disease by removing lipofuscin from retinal pigment epithelial (RPE) cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | In Stock | In Stock | |
| 2 mg | $236 | In Stock | In Stock | |
| 5 mg | $446 | In Stock | In Stock | |
| 10 mg | $745 | In Stock | In Stock | |
| 25 mg | $1,150 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $359 | In Stock | In Stock |
| Description | Soraprazan (BYK61359) is a selective potassium channel inhibitor that inhibits gastric acid secretion and ameliorates age-related eye disease by removing lipofuscin from retinal pigment epithelial (RPE) cells. |
| Targets&IC50 | 1 mM potassium ions (ion-loss vesicles):0.1 μM, [14C]-AP:0.19 μM |
| In vitro | Soraprazan is a potent inhibitor of gastric H,K-ATPase, with an IC50 value of 0.1 μM in the presence of 1 mM potassium ions in ion-loss vesicles, and inhibits dibutyryl cyclic AMP-stimulated [14C]AP accumulation in isolated gastric glands with an IC50 value of 0.19 μM. [1] |
| In vivo | Soraprazan 1-27 μmol/kg administered orally showed rapid and stable inhibition of acid secretion in dogs.[1] |
| Synonyms | BYK61359, BYK 61359 |
| Molecular Weight | 367.44 |
| Formula | C21H25N3O3 |
| Cas No. | 261944-46-1 |
| Smiles | O(CCOC)[C@@H]1C2=C(C=3N(C=C2)C(C)=C(C)N3)N[C@@H]([C@H]1O)C4=CC=CC=C4 |
| Relative Density. | 1.29 g/cm3 (Predicted) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (217.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.